Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Advertising Enforcement Turns Its Focus To YouTube, ADHD Drugs

Executive Summary

FDA's spate of five promotional citations to manufacturers of attention deficit/hyperactivity disorder drugs signals that the agency intends to remain vigilant in oversight of new media
Advertisement

Related Content

Luvox CR Symptom Benefit Claims Draw DDMAC Warning
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links
PhRMA’s Revised DTC Code Shies Away From Internet; Not Celebrities
New Media Is The New Frontier For Drug Promotion
Another celebrity pitch from Shire
Advertising Citations Reach Record High: Another Way To Regulate Pharma?
DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond
DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond
Wiki-How: FDLI Panel Cautions Firms On New Media Use
Pfizer’s “Viva Viagra” Ad Skips A Beat On Safety Risks; FDA Issues Warning Letter
Advertisement
UsernamePublicRestriction

Register

PS050175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel